drugset

drugset / Trial / NCT05633459

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

NCT05633459 ↗

Phase 1 Active not recruiting 69 enrolled QurAlis Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS

Timeline

Start: 2022-12-16
Primary completion: 2026-05-29
Completion: 2027-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QRL-201	Unknown	—	Intrathecal

Indications